Cat /

Breed profile · FDA CVM July 2026 extract

Domestic Shorthair adverse-event record

Adverse-event filings for Domestic Shorthair (Cat) in the FDA Center for Veterinary Medicine openFDA extract. Browse cat breeds, reactions, and outcomes below.

Verify with FDA CVM →
#3 of 510
by report volume (all breeds)
65,226
FDA CVM reports on file
7.2%
death-coded share of reports
#80 of 275
by death-coded share (≥50 reports)

How the 65,226 reports break down

By recorded gender -- every report on file for Domestic Shorthair, no filtering.

Annual report volume

Annual adverse-event report trend Yearly FDA CVM adverse-event report counts for this breed. 8,457 6,342.75 4,228.5 2,114.25 0 2019 2020 2021 2022 2023 2024 2025 2026 Reports filed Death-coded reports
Annual report volume for Domestic Shorthair drawn from FDA CVM filings.

Data updated September 2026

The verdict

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Domestic Shorthair ranks #3 of 510 by total reports (65,226) and #80 of 275 by death-coded share (7.2%). National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).

93,675
Retriever - Labrador reports (#1)
99.0%
Atlantic Salmon (Salmo salar) death share (#1)
#3
This breed, reports of 510
#80
This breed, death share of 275

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Domestic Shorthair has 65,226 reports now versus 63,578 in that prior snapshot: 1,648 more (2.6%).

Report change
+1,648
Death-coded reports
+96
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Domestic Shorthair changes

Total Reports

65,226

Highest-reported breed

Deaths Reported

4,716

of 65,226 reports

Death-coded share of reports

7.2%

Above-median death-coded share

Avg Age at Report

7.1 yr

4.9 kg avg weight

Breed Safety Scorecard

F (24/100)

A weighted composite across 4 of 4 dimensions, each benchmarked against every tracked breed with at least 200 reports (n=185). Dimensions with insufficient data drop out and their weight redistributes to the rest, so a missing input never silently deflates the score.

Death rate F
7.2%

Share of reports coded as a fatality

Euthanasia rate F
3.5%

Share of reports resulting in euthanasia

Full recovery rate D
27.8%

Share of reports coded "Recovered/Normal"

5-year trend F
+111%

Change in annual report volume over the last 5 complete years

Death-Coded Outcome Share

Domestic Shorthair death-coded reports 7.2%
Cross-breed median

7.2% of 65,226 domestic shorthair reports involved a death outcome.

How to read this number

Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.

Where Domestic Shorthair's death-coded share sits among indexed breeds

Death-coded share of FDA CVM reports, breeds with ≥50 reports (July 2026 extract)

7% 71st percentile Higher share than 71% of 275 indexed breeds

5%–10%: 1 indexed breeds (0%). This entry sits in this band. 20%–25%: 2 indexed breeds (1%). Above this entry. 25%–30%: 3 indexed breeds (1%). Above this entry. 30%–35%: 4 indexed breeds (1%). Above this entry. 35%–40%: 5 indexed breeds (2%). Above this entry. 40%–45%: 6 indexed breeds (2%). Above this entry. 45%–50%: 3 indexed breeds (1%). Above this entry. 50%–55%: 7 indexed breeds (3%). Above this entry. 55%–60%: 7 indexed breeds (3%). Above this entry. 60%–65%: 21 indexed breeds (8%). Above this entry. 65%–70%: 11 indexed breeds (4%). Above this entry. 70%–75%: 15 indexed breeds (5%). Above this entry. 75%–80%: 13 indexed breeds (5%). Above this entry. 80%–85%: 11 indexed breeds (4%). Above this entry. 85%–90%: 12 indexed breeds (4%). Above this entry. 90%–95%: 12 indexed breeds (4%). Above this entry. 95%–100%: 142 indexed breeds (52%). Above this entry. Domestic Shorthair 5% 100% every breed with ≥50 FDA reports, bucketed by value

Each bar is a band; taller bars hold more indexed breeds. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source FDA Center for Veterinary Medicine, openFDA adverse event extract (PlainBreed) · July 2026 extract

This histogram uses the same ≥50-report cohort as the highest death-coded share ranking. A higher share means more of this breed's reported events were death-coded, not a mortality rate for living animals.

Domestic Shorthair among report-volume vs. death-rate peers

Every breed shown has at least 50 filed reports. Volume reflects how often a breed is reported, not how common it is; death rate is the share of a breed's own reports coded as a death outcome.

Source: FDA openFDA Animal & Veterinary Adverse Events database 2×2 strategic matrix plotting 30 entities by Total Reports (X) and Death Rate (%) (Y), with a crosshair dividing the plot into four quadrants. High volume, high death rateLow volume, high death rateHigh volume, low death rateLow volume, low death rate 020,00040,00060,00080,000100,000 0%5%10%15% Total Reports Death Rate (%) Domestic Shorthair vs. all breeds, report volume and death-coded share Retriever - Labrador-93675, 3.7%Crossbred Canine/dog-70591, 3.2%Domestic Shorthair-65226, 7.2%Dog (unknown)-48820, 8.8%Retriever - Golden-35980, 3.7%Shepherd Dog - German-32220, 4.4%Chihuahua-31521, 4.2%Terrier - Yorkshire-24924, 3.7%Shih Tzu-24405, 3.6%Boxer (German Boxer)-19405, 4.4%Beagle-17970, 3.6%Pit Bull-17865, 3.1%Shepherd Dog - Australian-16274, 3.7%Terrier (unspecified)-14058, 3.1%Maltese-13940, 3.2%Dachshund (unspecified)-13512, 4.6%Cat (unknown)-13248, 9.3%Terrier - Jack Russell-10423, 3.7%Collie - Border-10130, 4.3%Siberian Husky-9811, 4.5%Domestic Longhair-9615, 7%Pug-9224, 5.2%Spitz - German Pomeranian-9086, 4.9%Terrier - Bull - American Pit-8769, 4.7%Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog)-7871, 3.6%Terrier - Boston-7737, 4.5%Spaniel - Cocker American-7640, 4%Domestic (unspecified)-7576, 13.4%Poodle (unspecified)-7534, 3.4%Schnauzer - Miniature-7513, 4.4%
Source: FDA openFDA Animal & Veterinary Adverse Events database
Average weight at time of report: 4.9 kg (10.8 lbs)

Top Reported Reactions

Vomiting 8,026
Lethargy (see also Central nervous system depression in 'Neurological') 5,956
Application site hair loss 5,339
Lack of efficacy (ectoparasite) - flea 4,717
Lack of efficacy - NOS 3,744
Application site alopecia 3,623
Weight loss 3,505
Anorexia 3,492
Emesis 3,454
Behavioural disorder NOS 3,407
Diarrhoea 3,135
Lethargy (see also Central nervous system depression in Neurological) 2,740
Not eating 2,685
Hypersalivation 2,663
Ataxia 2,556

Most Referenced Drugs

Selamectin 6,749
Spinosad 6,482
Fluralaner Spot-On Solution 6,196
Frunevetmab 4,660
Selamectin;Sarolaner 4,530
Imidacloprid + Moxidectin 3,813
Nitenpyram 3,468
Cefovecin 3,449
Emodepside + Praziquantel 3,199
Buprenorphine 2,994
Velagliflozin Proline Monohydrate 2,799
Bexagliflozin 2,384
Maropitant Citrate 2,001
Fluralaner/Moxidectin Spot-On 1,971
Robenacoxib 1,853

Outcome Breakdown

Ongoing
22,205 (34.0%)
Outcome Unknown
19,849 (30.4%)
Recovered/Normal
18,116 (27.7%)
Died
2,423 (3.7%)
Euthanized
2,295 (3.5%)
Recovered with Sequela
408 (0.6%)

Gender Distribution

Male 34,459 (52.8%)
Female 29,477 (45.2%)
Unknown 873 (1.3%)
Mixed 417 (0.6%)

Reports by Year

Year Reports Trend
2010 134
2011 828
2012 2,573
2013 3,930
2014 3,457
2015 3,519
2016 3,741
2017 4,466
2018 4,197
2019 4,257
2020 3,747
2021 3,407
2022 3,701
2023 6,458
2024 8,457
2025 7,197
2026 1,157

Domestic Shorthair: high death-coded share in the FDA CVM extract

Signature read: 65,226 reports place Domestic Shorthair in the upper third of breed filing volume (#3 of 510). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Domestic Shorthair sits at #3 of 510 by report volume among all breeds and #1 of 55 among cat breeds, with 65,226 reports and 4,716 (7.2%) death-coded. On death-coded share among breeds with ≥50 reports, it ranks #80 of 275. Mean age at report: 7.1 years, average weight 4.9 kg (10.8 lbs).

Top reported signs: Vomiting (8,026), Lethargy (see also Central nervous system depression in 'Neurological') (5,956), Application site hair loss (5,339). Most-referenced drug: Selamectin (6,749 reports), followed by Spinosad (6,482) and Fluralaner Spot-On Solution (6,196).

Outcome coding on 65,296 status-recorded reports is dominated by Ongoing (34.0%). Annual submissions ranged 134-2,026 across 17 years on file.

Domestic Shorthair Reporting Concentration Profile

Domestic Shorthair is a high-volume FDA CVM cohort (65,226 reports) - enough filings to measure how concentrated the reaction and drug mix is, not just the headline totals. Across 20 named reaction terms in the stored top list, the leading three (Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Application site hair loss) account for 27.8% of listed reaction mentions. The Herfindahl index on that list is 0.059 (1.0 = a single reaction owns every mention; lower = a broader clinical mix).

On the drug side, 20 referenced products appear in the top list; the leading three (Selamectin, Spinosad, Fluralaner Spot-On Solution) cover 31.0% of those mentions. That multi-product footprint is the profile thin-report breeds cannot show - their pages stop at a short bar list because the sample cannot support a concentration read.

Outcome coding on 65,296 status-recorded filings splits roughly 7.2% severe (died or euthanized - 4,718 reports) versus 28.4% recovered or recovered-with-sequela (18,524). Read that split next to the 7.2% death-coded share above - both track reporting severity bias in a popular breed, not a proven mortality rate.

Peak filing year was 2024 (8,457 reports); the lightest year on file was 2010 (134). From 2024 to 2025, annual volume fell 14.9% (8,457 → 7,197). Year-to-year swings at this volume usually track product launches, owner awareness, and reporting campaigns more than sudden breed-health shocks.

Cat Breeds With a Similar Report Volume

Showing 6 of 54 cat breeds in our dataset, ranked by closest report volume.

Cat (unknown)
13,248 reports · 9.3% death-coded
Domestic Longhair
9,615 reports · 7.0% death-coded
Domestic (unspecified)
7,576 reports · 13.4% death-coded
Domestic Mediumhair
6,441 reports · 7.7% death-coded
Cat (other)
4,798 reports · 9.7% death-coded
Siamese
3,073 reports · 8.1% death-coded

Nationwide breeds with similar profiles

High-volume peer sets for Domestic Shorthair drawn from openFDA outside the Cat family so the neighborhoods are not species containment (the similar-volume list above stays within species).

What to do with this cat

A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.

Frequently Asked Questions

How many FDA adverse event reports involve Domestic Shorthair? ▼
There are 65,226 adverse event reports involving Domestic Shorthair in the FDA database, of which 4,716 were death-coded (7.2% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, Domestic Shorthair ranks #3 of 510 by report volume among all breeds PlainBreed indexes (#1 of 55 among cat breeds).
Where does Domestic Shorthair sit among other breeds in PlainBreed's corpus? ▼
According to FDA CVM report volume, Domestic Shorthair is #3 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Cat, it is #1 of 55. Among breeds with at least 50 reports, its death-coded share ranks #80 of 275 (same cohort as highest-death-rate). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for Domestic Shorthair? ▼
The most commonly reported adverse reactions for Domestic Shorthair are Vomiting (8,026 reports), Lethargy (see also Central nervous system depression in 'Neurological') (5,956 reports), Application site hair loss (5,339 reports), Lack of efficacy (ectoparasite) - flea (4,717 reports), Lack of efficacy - NOS (3,744 reports).
What drugs are most frequently associated with Domestic Shorthair adverse events? ▼
The drugs most frequently referenced in Domestic Shorthair adverse event reports are Selamectin (6,749 reports), Spinosad (6,482 reports), Fluralaner Spot-On Solution (6,196 reports), Frunevetmab (4,660 reports), Selamectin;Sarolaner (4,530 reports).
What is the average age of Domestic Shorthair in adverse event reports? ▼
The average age of Domestic Shorthair at the time of adverse event reports is 7.1 years, with an average weight of 4.9 kg (10.8 lbs).

Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Domestic Shorthair (Cat), extract as of July 2026 extract. 65,226 reports · 4,716 death-coded (7.2% of reports, not a mortality rate) · #3 of 510 by volume.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →